You are here

  • Home
  • Archive
  • Volume 17, Issue 2
  • Short- and long-term treatment with non-steroidal anti-inflammatory drugs increases risk of death or recurrent MI in those with previous MI

Article Text

Article menu
Download PDFPDF
Prognosis
Cohort study
Short- and long-term treatment with non-steroidal anti-inflammatory drugs increases risk of death or recurrent MI in those with previous MI
  1. Anjan K Chakrabarti,
  2. C Michael Gibson
  1. Department of Cardiology, Beth Israel Deaconess Medical Center, Boston Massachusetts, USA
  1. Correspondence to: Anjan K Chakrabarti
    Beth Israel Deaconess Medical Center, 185 Pilgrim Road, Baker 4, Boston MA 02215, USA; akchakra{at}bidmc.harvard.edu

https://doi.org/10.1136/ebm.2011.100132

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Schjerning Olsen AM, Fosbøl EL, Lindhardsen J, et al. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation 2011;123:2226–35.OpenUrlAbstract/FREE Full Text

    Context

    Non-steroidal anti-inflammatory drugs (NSAIDs) have been implicated in causing negative cardiovascular outcomes, particularly in coronary artery disease (CAD) patients who have had a prior myocardial infarction (MI). In fact, as Schjerning Olsen and colleagues point out, current guidelines give the rather nebulous recommendation that duration of NSAID therapy should be as short as possible in CAD patients.1

    The study by Schjerning Olsen and colleagues seeks to characterise the association between NSAID treatment duration and risk of cardiovascular disease. Although selective cyclooxygenase 2 inhibitors (COX-2) such as rofecoxib and valdecoxib have received notoriety and …

    View Full Text

    Footnotes

    • Competing interests None.